Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Editorial Board Member: Gillery, Philippe / Kazmierczak, Steven / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Whitfield, John B.

12 Issues per year

IMPACT FACTOR 2013: 2.955
Rank 5 out of 29 in category Medical Laboratory Technology in the 2013 Thomson Reuters Journal Citation Report/Science Edition

VolumeIssuePage

Issues

Development of des-γ-carboxy prothrombin (DCP) measuring reagent using the LiBASys clinical analyzer

Isao Yamaguchi1 / Kenji Nakamura2 / Hiromichi Kitano3 / Yoshie Masuda4 / Futoshi Kanke5 / Shinzo Kobatake6 / Shinji Satomura7

1New Diagnostics Business and Technology Development Department, Wako Pure Chemical Industries Ltd., Hyogo, Japan

2New Diagnostics Business and Technology Development Department, Wako Pure Chemical Industries Ltd., Hyogo, Japan

3New Diagnostics Business and Technology Development Department, Wako Pure Chemical Industries Ltd., Hyogo, Japan

4New Diagnostics Business and Technology Development Department, Wako Pure Chemical Industries Ltd., Hyogo, Japan

5New Diagnostics Business and Technology Development Department, Wako Pure Chemical Industries Ltd., Hyogo, Japan

6New Diagnostics Business and Technology Development Department, Wako Pure Chemical Industries Ltd., Hyogo, Japan

7New Diagnostics Business and Technology Development Department, Wako Pure Chemical Industries Ltd., Hyogo, Japan

Corresponding author: Isao Yamaguchi, New Diagnostics Business and Technology Development Department, Wako Pure Chemical Industries, Ltd., 6-1 Takada-cho, Amagasaki, Hyogo, 661-0963, Japan Phone: +81-6-6499-9109, Fax: +81-6-6499-1524,

Citation Information: Clinical Chemical Laboratory Medicine. Volume 46, Issue 3, Pages 411–416, ISSN (Online) 14374331, ISSN (Print) 14346621, DOI: 10.1515/CCLM.2008.078, February 2008

Publication History

Received:
2007-09-10
Accepted:
2007-11-23
Published Online:
2008-02-06

Abstract

Background: Des-γ-carboxy prothrombin (DCP), Lens culinaris agglutinin-reactive α-fetoprotein ratio (AFP-L3) and total α-fetoprotein (AFP) are tumor markers useful for diagnosing and determining the prognosis of hepatocellular carcinoma (HCC). There is a real need for measurement of these three markers on a one-assay platform.

Methods: A method of DCP measurement in human serum was developed using liquid binding assay (LBA), which enables rapid antigen-antibody reaction and bound/free separation on the LiBASys clinical analyzer.

Results: The dilution curve for DCP was linear up to 500 ng/mL. The limit of detection of DCP concentration was 0.5 ng/mL. Intra- and inter-assay coefficients of variation of DCP were 0.7%–2.4% and 2.2%–6.5%, respectively. This method was free from interference by hemoglobin, bilirubin, ditaurobilirubin, intrafat, ascorbate, galactose, glucose and rheumatoid factor. The analytical recoveries of DCP added to serum were 91.7%–108.2%. DCP concentration measured with the LBA method was linear and was significantly correlated with that measured with the ELISA method.

Conclusions: The LiBASys clinical analyzer made possible measurement of the complementary tumor markers, HCC, total AFP, AFP-L3 and DCP.

Clin Chem Lab Med 2008;46:411–6.

Keywords: des-γ-carboxy-prothrombin; hepatocellular carcinoma; Lens culinaris agglutinin-reactive α-fetoprotein ratio (AFP-L3); LiBASys; total α-fetoprotein (AFP)

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.